Novartis nabs EU clearance for Jetrea; Roche's hep C drug Pegasys wins new use

Novartis ($NVS) won European approval for its eye drug Jetrea, as a treatment for vitreomacular traction, which can cause progressive and irreversible vision loss. The European Medicines Agency also approved a new use for Roche's ($RHHBY) hepatitis C drug Pegasys, in children and adolescents aged 5 years and older. Release | Release

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.